Biosimilars in the United States: Current Status and Future Implications
Biosimilars in the United States: Current Status and Future Implications
June 13, 2019
1 min read
Save

FDA approves Kanjinti, biosimilar to Herceptin

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA approved trastuzumab-anns for the treatment of HER2-overexpressing breast cancer, as well as metastatic gastric or gastroesophageal junction adenocarcinoma.

Trastuzumab-anns (Kanjinti, Amgen) — a HER2 receptor antagonist — is a biosimilar to trastuzumab (Herceptin, Genentech).

Trastuzumab-anns is the fifth biosimilar to trastuzumab to receive FDA approval.

Biosimilars are biological products that have been shown to be highly similar to an already-approved biological product. The preapproved agents are called reference products.

Biosimilars must have no clinically meaningful differences from their reference products with regard to effectiveness or safety. Only small differences in clinically inactive components are allowable with biosimilar products.